Gain Therapeutics Inc. (GANX)
NASDAQ: GANX
· Real-Time Price · USD
1.81
0.27 (17.53%)
At close: Aug 15, 2025, 2:37 PM
17.53% (1D)
| Bid | 1.78 |
| Market Cap | 65.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.93M |
| EPS (ttm) | -0.59 |
| PE Ratio (ttm) | -3.07 |
| Forward PE | -2.03 |
| Analyst | Buy |
| Ask | 1.87 |
| Volume | 1,176,330 |
| Avg. Volume (20D) | 269,348 |
| Open | 1.53 |
| Previous Close | 1.54 |
| Day's Range | 1.51 - 2.12 |
| 52-Week Range | 0.95 - 3.19 |
| Beta | 0.11 |
About GANX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GANX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GANX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts9 months ago
+14.68%
Gain Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
10 months ago
+17.03%
Gain Therapeutics shares are trading higher after the company announced the presentation of new evidence supporting the disease-modifying activity of Gt-02287 in preclinical animal models of both GBA-1 and idiopathic Parkinson's disease.
